Sensei biotherapeutics to present topline clinical data from the sns-101 phase i dose escalation study at the 2024 asco annual meeting

Boston, april 24, 2024 (globe newswire) -- sensei biotherapeutics, inc. (nasdaq: snse), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that topline clinical data from the monotherapy and combination dose escalation portion of its phase 1/2 trial of sns-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint vista (v-domain ig suppressor of t cell activation), will be presented in a poster presentation at the upcoming 2024 american society of clinical oncology (asco) annual meeting taking place in chicago, il, from may 31 – june 4, 2024.
SNSE Ratings Summary
SNSE Quant Ranking